138 related articles for article (PubMed ID: 36336889)
1. Cytokeratin and CD56 aberrant co-expression in diffuse large B-cell lymphoma, NOS misinterpreted as metastatic neuroendocrine carcinoma by FNAC.
Prevodnik VK; Gašljević G
Cytopathology; 2023 Mar; 34(2):165-168. PubMed ID: 36336889
[TBL] [Abstract][Full Text] [Related]
2. [Diffuse large B-cell lymphoma with aberrant expression of CD56: a clinicopathologic and immunohistochemical study].
Wang J; Zhang W; Ding W; Gao L; Yan J; Liao D; Zhao S; Liu W
Zhonghua Bing Li Xue Za Zhi; 2016 Feb; 45(2):78-82. PubMed ID: 26879426
[TBL] [Abstract][Full Text] [Related]
3. Aberrant expression of epithelial and neuroendocrine markers in alveolar rhabdomyosarcoma: a potentially serious diagnostic pitfall.
Bahrami A; Gown AM; Baird GS; Hicks MJ; Folpe AL
Mod Pathol; 2008 Jul; 21(7):795-806. PubMed ID: 18487991
[TBL] [Abstract][Full Text] [Related]
4. CD56 expression in basaloid anal squamous cell carcinoma - A potential diagnostic pitfall.
Madahian S; Judelson R; Zhu X; Meng X; Dresser K; Hutchinson L; Bledsoe JR
Ann Diagn Pathol; 2021 Aug; 53():151758. PubMed ID: 33989959
[TBL] [Abstract][Full Text] [Related]
5. CD56-positive diffuse large B-cell lymphoma/leukemia with
Liu Y; Shen J; Awal Issah M; Liu T; Zhou H; Fu H
J Int Med Res; 2020 May; 48(5):300060520918087. PubMed ID: 32363958
[TBL] [Abstract][Full Text] [Related]
6. Diffuse large B cell lymphoma expressing the natural killer cell marker CD56.
Sekita T; Tamaru JI; Isobe K; Harigaya K; Masuoka S; Katayama T; Kobayashi M; Mikata A
Pathol Int; 1999 Aug; 49(8):752-8. PubMed ID: 10504545
[TBL] [Abstract][Full Text] [Related]
7. Aberrant expression of TTF1, p63, and cytokeratins in a diffuse large B-cell lymphoma.
Chornenkyy Y; Lin X
Diagn Cytopathol; 2021 Feb; 49(2):E75-E79. PubMed ID: 32870599
[TBL] [Abstract][Full Text] [Related]
8. CD3+/CD16+CD56+ cell numbers in peripheral blood are correlated with higher tumor burden in patients with diffuse large B-cell lymphoma.
Hus I; Starosławska E; Bojarska-Junak A; Dobrzyńska-Rutkowska A; Surdacka A; Wdowiak P; Wasiak M; Kusz M; Twardosz A; Dmoszyńska A; Roliński J
Folia Histochem Cytobiol; 2011; 49(1):183-7. PubMed ID: 21526506
[TBL] [Abstract][Full Text] [Related]
9. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
[TBL] [Abstract][Full Text] [Related]
10. A reassessment of primary thyroid lymphoma: high-grade MALT-type lymphoma as a distinct subtype of diffuse large B-cell lymphoma.
Skacel M; Ross CW; Hsi ED
Histopathology; 2000 Jul; 37(1):10-8. PubMed ID: 10931213
[TBL] [Abstract][Full Text] [Related]
11. CD56-positive diffuse large B-cell lymphoma: possible association with extranodal involvement and bcl-6 expression.
Gomyo H; Kajimoto K; Miyata Y; Maeda A; Mizuno I; Yamamoto K; Obayashi C; Hanioka K; Murayama T
Hematology; 2010 Jun; 15(3):157-61. PubMed ID: 20557674
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous CD56+ large T-cell lymphoma associated with high serum concentration of IL-2.
Wasik MA; Sackstein R; Novick D; Butmarc JR; Zhang Q; Vonderheid EC; Kadin ME
Hum Pathol; 1996 Jul; 27(7):738-44. PubMed ID: 8698322
[TBL] [Abstract][Full Text] [Related]
13. CD3-positive diffuse large B-cell lymphoma relapses as CD3-negative large B-cell lymphoma: Loss of aberrant antigen expression in B-cell lymphoma after chemotherapy.
Yang LH; Ingersoll K; Zhao Y; Luedke C; Sebastian S; Wang E
Pathol Res Pract; 2018 Oct; 214(10):1738-1744. PubMed ID: 30025593
[TBL] [Abstract][Full Text] [Related]
14. Diffuse large B-cell lymphoma with aberrant expression of the T-cell antigens CD2 and CD7.
Sangle NA; Agarwal AM; Smock KJ; Leavitt MO; Warnke R; Bahler D; Perkins SL
Appl Immunohistochem Mol Morphol; 2011 Dec; 19(6):579-83. PubMed ID: 21836500
[TBL] [Abstract][Full Text] [Related]
15. Evidence-based review of genomic aberrations in diffuse large B cell lymphoma, not otherwise specified (DLBCL, NOS): Report from the cancer genomics consortium lymphoma working group.
Yenamandra AK; Smith RB; Senaratne TN; Kang SL; Fink JM; Corboy G; Hodge CA; Lu X; Mathew S; Crocker S; Fang M
Cancer Genet; 2022 Nov; 268-269():1-21. PubMed ID: 35970109
[TBL] [Abstract][Full Text] [Related]
16. [Immunophenotypes and prognosis of diffuse large B-cell lymphoma: a study of 500 cases].
Luo DL; Liu YH; Zhuang HG; Li L; Xu FP; Zhang F; Luo XL; Xu J
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):235-9. PubMed ID: 21615996
[TBL] [Abstract][Full Text] [Related]
17. Development of angioimmunoblastic T-cell lymphoma after treatment of diffuse large B-cell lymphoma: a case report and review of literature.
Wang Y; Xie B; Chen Y; Huang Z; Tan H
Int J Clin Exp Pathol; 2014; 7(6):3432-8. PubMed ID: 25031772
[TBL] [Abstract][Full Text] [Related]
18. Expression of neuroendocrine markers in non-neuroendocrine endometrial carcinomas.
Moritz AW; Schlumbrecht MP; Nadji M; Pinto A
Pathology; 2019 Jun; 51(4):369-374. PubMed ID: 31040050
[TBL] [Abstract][Full Text] [Related]
19. Cytokeratin in anaplastic large cell lymphoma.
Frierson HF; Bellafiore FJ; Gaffey MJ; McCary WS; Innes DJ; Williams ME
Mod Pathol; 1994 Apr; 7(3):317-21. PubMed ID: 7520170
[TBL] [Abstract][Full Text] [Related]
20. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm.
Chan JK; Sin VC; Wong KF; Ng CS; Tsang WY; Chan CH; Cheung MM; Lau WH
Blood; 1997 Jun; 89(12):4501-13. PubMed ID: 9192774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
